Literature DB >> 31907434

Immune agonist antibodies face critical test.

Ken Garber.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 31907434     DOI： 10.1038/d41573-019-00214-5

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  8 in total

1.  Intratumorally anchored cytokine therapy.

Authors:  K Dane Wittrup; Howard L Kaufman; Michael M Schmidt; Darrell J Irvine
Journal:  Expert Opin Drug Deliv       Date:  2022-06-02       Impact factor: 8.129

2.  Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist.

Authors:  Punit Upadhyaya; Johanna Lahdenranta; Kristen Hurov; Sailaja Battula; Rachel Dods; Eric Haines; Marianna Kleyman; Julia Kristensson; Jessica Kublin; Rachid Lani; Jun Ma; Gemma Mudd; Elizabeth Repash; Katerine Van Rietschoten; Tom Stephen; Fanglei You; Helen Harrison; Liuhong Chen; Kevin McDonnell; Philip Brandish; Nicholas Keen
Journal:  J Immunother Cancer       Date:  2021-01       Impact factor: 13.751

Review 3.  Transcriptional Regulation of Cancer Immune Checkpoints: Emerging Strategies for Immunotherapy.

Authors:  Simran Venkatraman; Jarek Meller; Suradej Hongeng; Rutaiwan Tohtong; Somchai Chutipongtanate
Journal:  Vaccines (Basel)       Date:  2020-12-04

4.  The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota.

Authors:  Stephen J Blake; Jane James; Feargal J Ryan; Jose Caparros-Martin; Georgina L Eden; Yee C Tee; John R Salamon; Saoirse C Benson; Damon J Tumes; Anastasia Sribnaia; Natalie E Stevens; John W Finnie; Hiroki Kobayashi; Deborah L White; Steve L Wesselingh; Fergal O'Gara; Miriam A Lynn; David J Lynn
Journal:  Cell Rep Med       Date:  2021-12-08

5.  More fuel for the fire: Gut microbes and toxicity to immune agonist antibodies in cancer.

Authors:  Manoj Chelvanambi; Jennifer A Wargo
Journal:  Cell Rep Med       Date:  2021-12-21

Review 6.  Targeted Anti-Tumor Immunotherapy Using Tumor Infiltrating Cells.

Authors:  Yifan Xie; Feng Xie; Lei Zhang; Xiaoxue Zhou; Jun Huang; Fangwei Wang; Jin Jin; Long Zhang; Linghui Zeng; Fangfang Zhou
Journal:  Adv Sci (Weinh)       Date:  2021-10-18       Impact factor: 16.806

7.  An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy.

Authors:  Sarah Chan; Nicole Belmar; Sun Ho; Bryan Rogers; Marcia Stickler; Michelle Graham; Eileen Lee; Ninian Tran; Dong Zhang; Priyanka Gupta; Mien Sho; Tracy MacDonough; Andrew Woolley; Han Kim; Hong Zhang; Wei Liu; Pingping Zheng; Zoltan Dezso; Kyle Halliwill; Michele Ceccarelli; Susan Rhodes; Archana Thakur; Charles M Forsyth; Mengli Xiong; Siu Sze Tan; Ramesh Iyer; Marc Lake; Enrico Digiammarino; Li Zhou; Lance Bigelow; Kenton Longenecker; Russell A Judge; Cassie Liu; Max Trumble; Jonathan P Remis; Melvin Fox; Belinda Cairns; Yoshiko Akamatsu; Diane Hollenbaugh; Fiona Harding; Hamsell M Alvarez
Journal:  Nat Cancer       Date:  2022-03-07

8.  Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology.

Authors:  Punit Upadhyaya; Julia Kristensson; Johanna Lahdenranta; Elizabeth Repash; Jun Ma; Jessica Kublin; Gemma E Mudd; Lia Luus; Phil Jeffrey; Kristen Hurov; Kevin McDonnell; Nicholas Keen
Journal:  J Med Chem       Date:  2022-07-12       Impact factor: 8.039
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.